5 Best Performing Biotech ETFs in 2024
The Putnam BioRevolution ETF (NYSE:SYNB) is designed to pursue long-term capital growth by investing in a carefully curated portfolio of 30-50 stocks.
Posts Tagged ‘NASDAQ:IBB’
11 Best Biotech ETFs To Buy
The new era in biotech is defined by the convergence of biology, data, and artificial intelligence.
12 Best Healthcare ETFs To Buy
In December 2022, BlackRock highlighted concerns about the performance for the healthcare sector in 2023.
12 Best Biotech ETFs To Buy
According to Precedence Research, the worldwide biotechnology market was valued at approximately $1,224.31 billion in 2022.
10 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the ten best small cap pharma stocks to buy.
Trumpdesivir: Operation Warp Speed, “Engage.”
The COVID-19 vaccine race officially goes into high gear with the announcement of USA’s plan to test the 6-odd top vaccine candidates across upwards of 150,000 volunteers (...
3 Mistakes To Avoid When Choosing The Perfect Closed-End Fund
The closed-end fund marketplace is one of over 500 offerings that span virtually every global asset class.
Trump Supporters Icahn, Paulson Score Huge Returns After Election Win
Just like Main Street, this election season also saw Wall Street divided into two factions based on who they supported.
Julian Robertson Likes Biotech, Talks Up Microsoft (MSFT), Apple (AAPL) & Gilead (GILD)
Legendary investor Julian Robertson, founder of Tiger Management, sees tremendous upside in biotech stocks right now. The billionaire told CNBC in a recent interview that fears...
Should You Buy iShares NASDAQ Biotechnology Index (ETF) (IBB)?
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies.
20 Stocks That Matter The Most To Financial Advisors
There are nearly 14 million high net worth individuals in the world today.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN): Invest in the Next Biotech Frontier
The last several months have been remarkably exciting in the biotech space.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Have You Considered Biotech Yet?
We are in the midst of the earnings season, my favorite time of the year.
Amgen, Inc. (AMGN), Celgene Corporation (CELG): Is Big Biotech Still Growing?
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Pharma News: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & ACADIA Pharmaceuticals Inc. (ACAD)
Editor's Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc.
Biotechs Lose Ground As Achillion Pharmaceuticals, Inc. (ACHN) Takes a Dive
Biotechnology's a volatile sector that can intimidate many investors, but it's also a landscape of stocks that can reward portfolios with giant gains.
3D Systems Corporation (DDD) News: Phenix Systems Play, Geomagic Solutions, & Higher Market Cap Than Avery Dennison Corp (AVY)
Editor's Note: Related tickers: 3D Systems Corporation (NYSE:DDD), Stratasys, Ltd.
Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Is College Debt a Drag on These Promising Healthcare Stocks
Some stocks seem to have all the luck, offering the best of both worlds.
Under The Hood: An Unheralded Biotech ETF – iShares NASDAQ Biotechnology Index (IBB)
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Is This the Next Investing Bubble?
With the Nasdaq Biotechnology Index hitting record highs, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about whether we're in...
Buy, Sell, or Hold: Vical Incorporated (VICL)
When considering any stock for your portfolio, don't be swayed by just the positives.
Buy, Sell, or Hold: Astex Pharmaceuticals, Inc. (ASTX)
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons and decide whether its possible upside outweighs its risks.
